TABLE 3.

BASELINE AND 1-MONTH SEROTYPE-SPECIFIC GEOMETRIC MEAN IgG ANTIBODY LEVELS

	Baseline IgG μg/ml (95% CI)		1-Month IgG μg/ml (95% CI)
Serotype	PCV7	PPSV23	PCV7	PPSV23
4	0.26 (0.17–0.38)	0.32 (0.23–0.44)	2.03 (1.24–3.32)	0.70 (0.47–1.03)
6B	0.90 (0.65–1.25)	0.85 (0.67–1.08)	2.96 (1.96–4.48)	1.76 (1.23–2.52)
9V	0.86 (0.61–1.20)	0.76 (0.55–1.06)	4.69 (3.27–6.74)	2.09 (1.47–2.97)
14	2.88 (1.86–4.46)	2.90 (1.96–4.27)	17.2 (11.7–25.3)	11.22 (7.42–16.96)
18C	1.26 (0.84–1.89)	1.17 (0.83–1.64)	9.26 (6.29–13.6)	3.70 (2.58–5.29)
19F	3.20 (2.43–4.21)	3.16 (2.55–3.93)	7.33 (5.16–10.4)	6.20 (4.75–8.09)
23F	0.75 (0.52–1.07)	0.55 (0.40– 0.76)	7.31 (4.56–11.7)	1.52 (0.99–2.32)

Definition of abbreviations: OPK = opsonophagocytosis killing index; PCV7 = 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.

Within each study group, postvaccination antibody levels and OPK were higher than baseline (P < 0.01) for all serotypes. Bolded items represent a significant difference in absolute postvaccination IgG levels between vaccine groups and underlined items represent a significant difference in 1 month to baseline IgG ratio.